Short answer
Immunovant, Inc. (IMVT) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal first-quarter results ended June 30, 2026, released August 6, 2026.
Immunovant, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal first-quarter results ended June 30, 2026, released August 6, 2026
- Full financial details contained in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- IMVT-1402 timelines remain on track across six autoimmune indications, with GD and MG topline data expected in 2027
- Cash $797.8M supports potential IMVT-1402 launch in GD, but quarterly cash declined from $902.1M at March 31, 2026
- R&D expense rose to $142.6M from $101.2M, reflecting expanded IMVT-1402 trials and contract manufacturing costs
- Net loss widened to $153.2M, or $0.75 per share, from $120.6M, or $0.71 per share
- Shares outstanding increased to 206.3M from 203.9M, indicating potential dilution for existing shareholders
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Immunovant, Inc. 8-K filings
Get the next IMVT 8-K as it lands
Follow IMVT for push alerts, or ask the research agent what this filing means.